NCT01384877View on ClinicalTrials.gov

Subcutaneous Lidocaine For Cancer-Related Pain

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2017

Study Completion Date

January 31, 2019

Conditions
Cancer-related Pain
Interventions
DRUG

Lidocaine

10mg/kg by subcutaneous infusion over 5.5 hours

DRUG

Placebo (D5W)

Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)

Trial Locations (2)

V2M 7E9

BC Cancer Center of the North, Prince George

V5Z 4E6

BC Cancer Agency, Vancouver

All Listed Sponsors
collaborator

BC Cancer Foundation

OTHER

lead

British Columbia Cancer Agency

OTHER

NCT01384877 - Subcutaneous Lidocaine For Cancer-Related Pain | Biotech Hunter | Biotech Hunter